These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6117305)

  • 41. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis.
    James LP; Stowe CD; Farrar HC; Menendez AA; Argao EA
    J Clin Pharmacol; 1999 Dec; 39(12):1242-7. PubMed ID: 10586389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacokinetics of ranitidine.
    Roberts CJ
    Clin Pharmacokinet; 1984; 9(3):211-21. PubMed ID: 6329583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ranitidine influences the uptake of oral midazolam.
    Elwood RJ; Hildebrand PJ; Dundee JW; Collier PS
    Br J Clin Pharmacol; 1983 Jun; 15(6):743-5. PubMed ID: 6135440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The new histamine H2-receptor antagonist ranitidine. Duration of action.
    Dammann HG; Simon B
    Scand J Gastroenterol Suppl; 1981 Jun; 69():39-43. PubMed ID: 6119781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers.
    Tenero DM; Martin DE; Ilson BE; Boyle DA; Boike SC; Carr AM; Lundberg DE; Jorkasky DK
    Ann Pharmacother; 1998 Mar; 32(3):304-8. PubMed ID: 9533060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genotoxicity of nitrosated ranitidine.
    De Flora S; Bennicelli C; Camoirano A; Zanacchi P
    Carcinogenesis; 1983; 4(3):255-60. PubMed ID: 6131752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.
    Brogden RN; Carmine AA; Heel RC; Speight TM; Avery GS
    Drugs; 1982 Oct; 24(4):267-303. PubMed ID: 6128216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.
    Takabatake T; Ohta H; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Satoh S; Hattori N
    Eur J Clin Pharmacol; 1986; 30(6):709-12. PubMed ID: 2876900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of ranitidine on the disposition of lignocaine.
    Robson RA; Wing LM; Miners JO; Lillywhite KJ; Birkett DJ
    Br J Clin Pharmacol; 1985 Aug; 20(2):170-3. PubMed ID: 4041336
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The pharmacokinetics of H2 receptor blocking agents in compensated liver cirrhosis.
    Okolicsányi L; Venuti M; Strazzabosco M; Iemmolo RM; Nassuato G; Orlando R; Lirussi F
    Acta Physiol Hung; 1984; 64(3-4):393-400. PubMed ID: 6099684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers.
    Delhotal-Landes B; Flouvat B; Liote F; Abel L; Meyer P; Vinceneux P; Carbon C
    Clin Pharmacol Ther; 1988 Oct; 44(4):442-52. PubMed ID: 2901930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and pharmacodynamics of ranitidine in renal impairment.
    Koch KM; Liu M; Davis IM; Shaw S; Yin Y
    Eur J Clin Pharmacol; 1997; 52(3):229-34. PubMed ID: 9218931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam.
    Greenblatt DJ; Locniskar A; Scavone JM; Blyden GT; Ochs HR; Harmatz JS; Shader RI
    Anesth Analg; 1986 Feb; 65(2):176-80. PubMed ID: 2935051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antagonism of vasodepressor and gastric secretory responses to histamine by the H2-receptor antagonists, ranitidine and cimetidine, in the anaesthetized dog.
    Daly MJ; Humphray JM; Stables R
    Br J Pharmacol; 1981 Jan; 72(1):55-60. PubMed ID: 6112035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of cotinine after oral and intravenous administration to man.
    De Schepper PJ; Van Hecken A; Daenens P; Van Rossum JM
    Eur J Clin Pharmacol; 1987; 31(5):583-8. PubMed ID: 3830243
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients.
    Roberts AP; Harrison C; Dixon GT; Curtis JR
    Postgrad Med J; 1983 Jan; 59(687):25-7. PubMed ID: 6135202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of cimetidine and ranitidine on the pharmacokinetics of quinine.
    Wanwimolruk S; Sunbhanich M; Pongmarutai M; Patamasucon P
    Br J Clin Pharmacol; 1986 Sep; 22(3):346-50. PubMed ID: 3768247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.